GHK-Cu vs Pasireotide
Overview
GHK-Cu is primarily a healing & recovery peptide, while Pasireotide is used for hormonal.
This page compares GHK-Cu and Pasireotide across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| GHK-Cu | Pasireotide | |
|---|---|---|
| Category | Healing & Recovery | Hormonal |
| Regulatory status (US) | Compounding (Rx) — Apr 2026 | FDA approved |
| Typical dosage | 1-3 mg | 0.6–0.9 mg SC twice daily (Cushing's disease, SC formulation) or 40–60 mg IM every 4 weeks (acromegaly, LAR); 10–40 mg IM every 4 weeks (Cushing's disease, LAR) |
| Frequency | daily | Twice daily (SC formulation) or every 4 weeks (LAR formulation) |
| Reported benefits | Wound healing, collagen synthesis, anti-inflammatory, antioxidant effects, tissue remodeling | Reduction of cortisol hypersecretion in Cushing's disease, normalization of GH and IGF-1 in acromegaly, pituitary tumor volume reduction, improvement of clinical signs of hypercortisolism |
| Reported side effects | Generally safe. Possible: mild skin irritation with topical use | Hyperglycemia, new-onset or worsening diabetes mellitus, diarrhea, nausea, cholelithiasis, QT interval prolongation, bradycardia, hepatic enzyme elevation, adrenal insufficiency (hypocortisolism) |
Key differences
Primary use. GHK-Cu is categorised under Healing & Recovery, while Pasireotide falls under Hormonal. Their differing categories mean they are usually chosen for different goals rather than as direct substitutes.
Regulatory status. GHK-Cu: not FDA-approved; compounding permitted with a prescription as of April 2026. Pasireotide: FDA-approved.
Dosing. GHK-Cu is typically dosed at 1-3 mg (daily). Pasireotide is typically dosed at 0.6–0.9 mg SC twice daily (Cushing's disease, SC formulation) or 40–60 mg IM every 4 weeks (acromegaly, LAR); 10–40 mg IM every 4 weeks (Cushing's disease, LAR) (Twice daily (SC formulation) or every 4 weeks (LAR formulation)).
Can you stack them?
Some protocols combine peptides, but stacking GHK-Cu and Pasireotide has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between GHK-Cu and Pasireotide?
- GHK-Cu is primarily a healing & recovery peptide, while Pasireotide is used for hormonal. GHK-Cu is not FDA-approved; compounding permitted with a prescription (as of April 2026), whereas Pasireotide is FDA-approved for one or more indications.
- What is GHK-Cu used for?
- Wound healing, skin regeneration.
- What is Pasireotide used for?
- Multi-receptor somatostatin analog (Signifor/Signifor LAR) FDA-approved for Cushing's disease and acromegaly.
- Can you take GHK-Cu and Pasireotide together?
- Some users combine peptides within a single protocol, but stacking GHK-Cu and Pasireotide has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is GHK-Cu or Pasireotide FDA-approved?
- GHK-Cu is not FDA-approved; compounding permitted with a prescription (as of April 2026). Pasireotide is FDA-approved for one or more indications.
Read the full articles
- GHK-Cu — full monograph: mechanism, research, dosing & references
- Pasireotide — full monograph: mechanism, research, dosing & references